glp-1 receptor agonist for weight loss Mechanisms of Agonist-Induced Loss: A Review of Central and Peripheral Pathways in Appetite and Energy Regulation Glucagon-like peptide-1 receptor agonists (GLP-1RAs)

PubMed research supports that insulin resistance is a core factor in various health issues beyond diabetes, including fatty liver, cognitive impairment, and cardiovascular disease (Springer)

Most notable is a study of cardiovascular outcomes among 2,287 patients with type 2 diabetes and obesity who underwent bariatric surgery at Cleveland Clinic and 11,435 matched controls ( JAMA

People who swapped GLP-1 drugs were more likely to stick with treatment 36% of switchers versus 21% of those who stuck with their first prescribed drug

Regular medical follow up is important for anyone taking these drugs over time

Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study

The REDEFINE 1 phase 3 trial showed CagriSema achieved 20.4% mean weight loss at 68 weeks in adults with obesity, with 60% of participants losing at least 20% of body weight ( [140] )